Key Highlights

  • Anagenics reported a net operating cash outflow of $10,000 for the September 2026 quarter, compared with about $0.3 million in the first quarter of FY2026.
  • Receipts from customers were $1.381 million, and cash at 30 September 2026 was $532,000.
  • The company received $446,000 of YSB Royalty income in the quarter and has invoiced $377,000 for the three months to 30 September, expected in October 2026.

Anagenics Limited (ASX:AN1) reported a net operating cash outflow of $10,000 for the September 2026 quarter, compared with about $0.3 million in the first quarter of FY2026. The figures are in its Appendix 4C and activity report for the first quarter of FY2027, released on 22 October 2026.

Anagenics operates in health, beauty and wellness, distributing proprietary and licensed anti-ageing brands globally. Its wholly owned subsidiary, BLC Cosmetics Pty Ltd, handles sales and distribution of Australian and international cosmetic and wellness brands. The company attributes the improvement in Operating Cash Flow of roughly $0.29 million to the restructuring of its operations.

The company states that it is now trading profitably and expects to generate operating cash flow going forward. It also says it continues to look for value-accretive opportunities consistent with its stated strategy, and the report does not identify any specific transaction or give a timetable.

Cash flow detail

Receipts from customers were $1.381 million for the quarter. The company paid $756,000 for product Manufacturing and operating costs, $42,000 for Advertising and marketing, $242,000 for staff and director costs, and $351,000 for administration and corporate costs. No amounts were reported for research and development, leased assets, interest, tax or grants. Net operating cash flow was an outflow of $10,000.

There were no investing cash flows. Financing activities consisted of $33,000 in repayments of borrowings and leasing, and the effect of exchange rates was a further $2,000 negative. Cash at 30 September 2026 was $532,000, made up of $390,000 in bank balances and $142,000 in call deposits. The company reports no bank overdraft and no financing facilities, either used or unused.

Royalty Revenue from the YSB product line

The report separately lists royalty income from the YSB product line. The company received $446,000 in the quarter, relating to an amount invoiced in June 2026 in the previous quarter. It has also invoiced $377,000 for the three months to 30 September 2026, which it expects to receive in October 2026. That second amount was invoiced but had not been received at quarter-end, so it is not included in the reported cash balance.

Funding estimate and related-party payments

On the standard Appendix 4C calculation, the company estimates 53.2 quarters of funding, derived by dividing closing cash of $532,000 by the $10,000 operating outflow. Because the figure is above two quarters, the additional funding questions in the form were not required. The company expects the operating outflow to remain small or turn positive.

Director fees of $31,000 were paid during the quarter, and there were no related-party payments in investing activities.

Presentation points

The document contains some internal differences. The company says it is trading profitably and expects positive operating cash flow, while the Appendix 4C shows a $10,000 net operating outflow. The opening cash line is blank, and the net change in cash is shown as 577, whereas the quarter's line items give a net decrease of about $45,000. The prior-quarter comparison column also matches the current quarter. The company has not clarified the presentation.

The report also does not describe specific product programmes, development milestones or dated targets beyond the restructuring and the timing of the YSB royalty receipt. The next dated event is the expected receipt of the $377,000 royalty in October 2026. Anagenics (ASX:AN1) has not provided guidance figures for future quarters beyond its statement of expected positive operating cash flow.